Table I.
Characteristics of the included studies.
| First author | Year | Follow-up | Treatment | N | Age (years) | M/F | Weight (kg) | Duration of psoriasis (years) | PASI score | PASI 75 | PASI 50 | PASI 90 | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laburte et al | 1994 | 0.2–18.3 | CSA 5 mg | 132 | 40.7±12.3 | 90/42 | 72.9±3.4 | 17.7±11.1 | 25.1±8.0 | 117 | NA | NA | (25) |
| months | CSA 2.5 mg | 119 | 42.0±12.6 | 86/33 | 77.4±15.5 | 18.4±11.1 | 24.9±7.0 | 57 | NA | NA | |||
| Gordon et al | 2006 | 60 weeks | Adalimumab | 45 | 46 (20–71) | 32/13 | 93 (63–159) | 21 (1.3–57.9) | 16.7 (5.4–39.0) | 24 | NA | NA | (17) |
| Placebo | 52 | 43 (20–70) | 34/18 | 94(50–147) | 19 (1.0–39.9) | 16.0(5.5–40.4) | 2 | NA | NA | ||||
| Menter et al | 2008 | 16 weeks | Adalimumab | 814 | 44.1±13.2 | 546/268 | 92.3±23.0 | 18.1±11.91 | 19.0±7.08 | 578 | NA | 366 | (2) |
| Placebo | 398 | 45.4±13.4 | 257/141 | 94.1±23.0 | 18.4±11.94 | 18.8±7.09 | 28 | NA | 8 | ||||
| Asahina et al | 2010 | 24 weeks | Adalimumab | 38 | 47.8±12.81 | 32/6 | 69.7±15.48 | 14.2±9.29 | 25.44±8.98 | 24 | 31 | 15 | (5) |
| Placebo | 46 | 43.9±10.75 | 41/5 | 71.3±15.28 | 15.5±8.83 | 29.10±11.77 | 2 | 9 | 0 | ||||
| Revicki et al | 2008 | 16 weeks | Adalimumab | 108 | 42.8±12.3 | 37/71 | NA | 17.6±10.0 | 20.1±7.4 | 86 | 95 | 55 | (34) |
| MTX | 110 | 41.9±11.9 | 36/74 | NA | 19.0±10.3 | 19.5±7.4 | 66 | 68 | 15 | ||||
| Placebo | 53 | 40.7±11.4 | 18/35 | NA | 18.9±8.7 | 19.2±6.9 | 10 | 16 | 6 | ||||
| Leonardi et al | 2003 | 12 weeks | Etanercept 50 mg BIW | 164 | 44.8±0.8 | 107/57 | NA | 18.6±0.9 | 18.4±0.7 | 81 | 121 | 36 | (27) |
| Etanercept 25 mg BIW | 162 | 45.4±1.0 | 109/53 | NA | 18.5±0.9 | 18.5±0.7 | 55 | 94 | 19 | ||||
| Etanercept 25 mg QW | 160 | 44.4±0.9 | 118/42 | NA | 19.3±0.9 | 18.2±0.7 | 23 | 65 | 5 | ||||
| Placebo | 166 | 45.6±1.0 | 105/61 | NA | 18.4±0.9 | 18.3±0.6 | 6 | 24 | 1 | ||||
| Papp et al | 2005 | 12 weeks | Etanercept 50 mg BIW | 194 | 44.5 (21.0–80.0) | 130/64 | NA | 18.1 (0.8–60.5) | 16.1 (7.0–57.3) | 96 | 150 | 40 | (32) |
| Etanercept 25 mg BIW | 196 | 46.0 (20.0–87.0) | 128/68 | NA | 21.5 (0.8–64.6) | 16.9 (4.0–51.2) | 67 | 126 | 21 | ||||
| Placebo | 193 | 44.0 (18.0–80.0) | 124/69 | NA | 17.5 (1.4–51.2) | 16.0 (7.0–62.4) | 6 | 18 | 1 | ||||
| Tyring et al | 2006 | 12 weeks | Etanercept 50 mg BIW | 311 | 45.8±12.8 | 203/108 | NA | 20.1±12.3 | 18.3±7.6 | 146 | 230 | 65 | (37) |
| Placebo | 307 | 45.6±12.1 | 216/91 | NA | 19.7±11.4 | 18.1±7.4 | 15 | 43 | 3 | ||||
| van de Kerkhof et al | 2008 | 12 weeks | Etanercept 25 mg BIW | 96 | 45.9±12.8 | 59/36 | 83.4±16.0 | 19.3±11.3 | 21.4±9.3 | 36 | 66 | 13 | (38) |
| Placebo | 46 | 43.6±12.6 | 25/21 | 79.1±20.2 | 17.3±8.2 | 21.0±8.7 | 1 | 4 | 1 | ||||
| Cassano et al | 2010 | 12 weeks | Etanercept 50 mg BIW | 36 | NA | NA | NA | NA | NA | 19 | 33 | NA | (40) |
| Etanercept 100 mg QW | 36 | NA | NA | NA | NA | NA | 13 | 27 | NA | ||||
| Strober et al | 2011 | 12 weeks | Etanercept 50 mg BIW | 139 | 45.2±14.8 | 85/54 | 96.9±24.9 | 15.2±12.1 | 18.5±6.0 | 55 | NA | 19 | (8) |
| Briakinumab | 139 | 44.9±12.9 | 93/46 | 96.1±24.5 | 16.3±12.0 | 19.4±7.9 | 112 | NA | 77 | ||||
| Placebo | 72 | 45.0±13.9 | 46/26 | 92.9±25.2 | 15.5±11.7 | 18.3±6.4 | 5 | NA | 3 | ||||
| Gottlieb et al | 2011 | 12 weeks | Etanercept 50 mg BIW | 141 | 43.1±12.5 | 98/43 | 94.5±20.4 | 17.0±12.7 | 19.4±8.0 | 78 | NA | 32 | (19) |
| Briakinumab | 138 | 43.6±14.3 | 89/49 | 93.2±22.9 | 16.1±12.5 | 18.4±7.2 | 113 | NA | 81 | ||||
| Placebo | 68 | 44.0±13.6 | 47/21 | 96.5±27.2 | 19.1±13.2 | 18.5±6.9 | 5 | NA | 1 | ||||
| Bagel et al | 2012 | 12 weeks | Etanercept 50 mg BIW | 62 | 39 (18.0–71.0) | 29/33 | 30.2 (18.2–44.2) | 17.5 (1–45) | 15.5 (8–46) | 37 | 53 | 16 | (8) |
| Placebo | 62 | 42 (18.0–70.0) | 26/36 | 30.2 (18.2–44.2) | 11.9 (1–49) | 15.2 (10–41) | 3 | 4 | 1 | ||||
| Gottlieb et al | 2003 | 10 weeks | Infliximab 5 mg | 99 | 44 (34, 53) | 73/26 | NA | 16 (10, 25) | 20 (14, 28) | 87 | 96 | 47 | (20) |
| Infliximab 3 mg | 99 | 45 (37, 55) | 70/29 | NA | 18 (12, 24) | 20 (15, 26) | 71 | 83 | 45 | ||||
| Placebo | 51 | 45 (30, 52) | 31/20 | NA | 16 (6, 22) | 18 (15, 27) | 3 | 11 | 1 | ||||
| Reich et al | 2005 | 24 weeks | Infliximab 5 mg | 301 | 42.6±11.7 | 207/94 | NA | 19.1±11.0 | 22.9±9.3 | 227 | 248 | 161 | (33) |
| Placebo | 77 | 43.8±12.6 | 61/16 | NA | 17.3±11.1 | 22.8±8.7 | 3 | 6 | 1 | ||||
| Menter et al | 2007 | 14 weeks | Infliximab 5 mg | 314 | 44.5±13.0 | 204/110 | 92.2±23.2 | 19.1±11.7 | 20.4±7.5 | 193 | 252 | 113 | (29) |
| Infliximab 3 mg | 313 | 43.4±12.6 | 206/107 | 92.0±22.5 | 18.1±11.8 | 20.1±7.9 | 149 | 213 | 75 | ||||
| Torii and Nakagawa | 2010 | 14 weeks | Infliximab 5 mg | 35 | 46.9±13.0 | 22/13 | 68.5±13.4 | 14.2±8.9 | 31.9±12.8 | 25 | 29 | 17 | (35) |
| Placebo | 19 | 43.3±12.3 | 14/5 | 69.7±8.9 | 11.1±6.5 | 33.1±15.6 | 2 | 2 | 1 | ||||
| Yang et al | 2012 | 10 weeks | Infliximab 5 mg | 84 | 39.4±12.3 | 60/24 | 68.2±9.2 | 16.0±10.8 | NA | 68 | 79 | 48 | (39) |
| Placebo | 45 | 40.1±11.1 | 35/10 | 67.4±9.9 | 16.0±8.9 | NA | 1 | 6 | 0 | ||||
| Barker et al | 2011 | 26 weeks | Infliximab 5 mg | 653 | 44.1 (±18–78) | 438/215 | 84.5±18.6 | 18.8±11.6 | 21.4±8.0 | 502 | 529 | 333 | (14) |
| MTX | 215 | 41.9 (±18–69) | 148/67 | 83.8±18.2 | 17.0±10.3 | 21.1±7.6 | 66 | 103 | 32 | ||||
| Leonardi et al | 2008 | 12 weeks | Ustekinumab 90 mg | 256 | 46.2±11.3 | 173/83 | 93.8±23.9 | 19.6±11.1 | 19.7±7.6 | 170 | 220 | 94 | (26) |
| Ustekinumab 45 mg | 255 | 44.8±12.5 | 175/80 | 93.7±23.8 | 19.7±11.7 | 20.5±8.6 | 171 | 213 | 106 | ||||
| Placebo | 255 | 44.8±11.3 | 183/72 | 94.2±23.5 | 20.4±11.7 | 20.4±8.6 | 8 | 26 | 5 | ||||
| Papp et al | 2008 | 12 weeks | Ustekinumab 90 mg | 411 | 46.6±12.1 | 274/137 | 91.5±21.3 | 20.3±12.3 | 20.1±7.5 | 311 | 367 | 209 | (31) |
| Ustekinumab 45 mg | 409 | 45.1±12.1 | 283/126 | 90.3±21.0 | 19.3±11.7 | 19.4±6.8 | 273 | 342 | 173 | ||||
| Placebo | 410 | 47.0±12.5 | 283/127 | 91.1±21.6 | 20.8±12.2 | 19.4±7.5 | 15 | 41 | 3 | ||||
| Griffiths | 2010 | 36 weeks | Ustekinumab 90 mg | 247 | NA | NA | NA | NA | NA | 183 | NA | 111 | (21) |
| Ustekinumab 45 mg | 209 | NA | NA | NA | NA | NA | 142 | NA | 75 | ||||
| Etanercept 50 mg BIW | 347 | NA | NA | NA | NA | NA | 198 | NA | 80 | ||||
| Tsai et al | 2011 | 12 weeks | Ustekinumab 45 mg | 61 | 40.9±12.7 | 50/11 | 73.1±12.7 | 11.9±7.5 | 25.2±11.9 | 41 | 51 | 30 | (36) |
| Placebo | 60 | 40.4±10.1 | 53/7 | 74.6±13.0 | 13.9±7.3 | 22.9±8.6 | 3 | 8 | 1 | ||||
| Igarashi et al | 2012 | 12 weeks | Ustekinumab 45 mg | 64 | M: 45.0 | 53/11 | 73.2±15.4 | 15.8±8.2 | 30.1±12.9 | 38 | 53 | 21 | (24) |
| Ustekinumab 90 mg | 62 | M: 44.0 | 47/15 | 71.1±14.0 | 17.3±10.7 | 28.7±11.2 | 42 | 52 | 27 | ||||
| Placebo | 32 | M: 49.0 | 26/6 | 71.2±10.9 | 16.0±11.2 | 30.3±11.8 | 2 | 4 | 1 | ||||
| Heydendael et al | 2003 | 17–52 weeks | CSA 2.5 mg | 42 | 41.6±13.0 | 29/13 | NA | NA | 14.0±6.6 | 30 | NA | NA | (22) |
| MTX | 43 | 38.3±12.4 | 28/15 | NA | NA | 13.4±3.6 | 26 | NA | NA | ||||
| Flytstrom et al | 2008 | CSA 5 mg | 31 | 45 (18–70) | 27/4 | 87 (61–130) | NA | 15.5±6.3 | 18 | 27 | 9 | (16) | |
| MTX | 37 | 48 (23–78) | 28/9 | 85 (56–132) | NA | 14.1±7.0 | 22 | 24 | 4 | ||||
| Ho et al | 2010 | 6 months | MTX | 20 | 38.45 (21–68) | 18/2 | NA | NA | NA | 13 | NA | 0 | (23) |
| Placebo | 20 | 43.45 (27–61) | 18/2 | NA | NA | NA | 16 | NA | 5 | ||||
| Gottlieb et al | 2003 | 24 weeks | Etanercept 25 mg BIW | 57 | 48.2 (25–72) | 33/24 | Mean: 91.8 | 23±1.6 | 17.8±1.1 | 17 | 40 | 6 | (20) |
| Placebo | 55 | 46.5 (18–77) | 37/18 | Mean: 90.7 | 20±1.7 | 19.5±1.3 | 1 | 6 | 0 | ||||
| Cassano et al | 2006 | 12 weeks | Etanercept 50 mg BIW | 53 | 42.3 (18–73) | 57/52 | NA | NA | 8.7 (5.4–11.6) | 29 | 39 | NA | (15) |
| Etanercept 100 mg QW | 55 | NA | NA | 28 | 43 | NA | |||||||
| Sterry et al | 2010 | 12 weeks | Etanercept 50 mg BIW | 379 | 46±11 | 243/136 | NA | 19±12 | 20±11 | 208 | NA | NA | (7) |
| Etanercept 50 mg QW | 373 | 47±11 | 230/143 | NA | 19±11 | 19±10 | 134 | NA | NA | ||||
| Antoni et al | 2005 | 16 weeks | Infliximab 5 mg | 52 | 45.7±11.1 | 30/22 | NA | 19.4±11.6 | 5.1±5.9 | 35 | NA | NA | (4) |
| Placebo | 52 | 45.2±9.7 | 30/22 | NA | 16.9±10.9 | 4.2±5.8 | 0 | NA | NA | ||||
| McInnes et al | 2013 | 12 weeks | Ustekinumab 45 mg | 205 | 48.0 (39.0–55.0) | 106/99 | NA | 12.0 (4.1–22.2) | 7.1 (3.3–15.3) | 83 | NA | NA | (28) |
| Ustekinumab 90 mg | 204 | 47.0 (38.5–54.0) | 116/88 | NA | 14.1 (5.4–22.4) | 8.4 (4.8–14.7) | 93 | NA | NA | ||||
| Placebo | 206 | 48.0 (39.0–57.0) | 108/98 | NA | 13.1 (5.3–23.5) | 8.8 (4.4–14.3) | 16 | NA | NA | ||||
| Griffiths et al | 2015 | 12 weeks | Etanercept 50 mg QW | 371 | 46.9±11.4 | 229 | NA | 18.6±11.4 | 19.0±9.8 | 148 | NA | NA | (6) |
| Etanercept 50 mg BIW | 377 | 46.1±11.4 | 241 | NA | 19.2±11.9 | 19.8±10.7 | 226 | NA | NA |
Data are presented as the mean ± standard deviation, or as the median (range). PASI, Psoriasis Area and Severity Index; MTX, methotrexate; CSA, cyclosporin A; BIW, twice weekly; QW, once weekly; M/F, male/female; NA, not available; Ref, study reference number; M, mean value.